TRADES
Latest Trades
139
results found
FUND
DATE
ACTION
TICKER
COMPANY
SHARES
% of ETF
ARKG 16 Sep 2022 Buy BEAM BEAM THERAPEUTICS INC 20,578 0.0419
ARKG 14 Sep 2022 Buy BEAM BEAM THERAPEUTICS INC 5,621 0.0112
ARKG 13 Sep 2022 Buy BEAM BEAM THERAPEUTICS INC 82,577 0.1545
ARKK 10 Aug 2022 Sell BEAM BEAM THERAPEUTICS INC 155,492 0.1052
ARKK 28 Jul 2022 Sell BEAM BEAM THERAPEUTICS INC 55,804 0.0384
ARKK 13 Jul 2022 Sell BEAM BEAM THERAPEUTICS INC 163,896 0.0953
ARKG 14 Apr 2022 Buy BEAM BEAM THERAPEUTICS INC 13,409 0.0193
ARKK 14 Apr 2022 Buy BEAM BEAM THERAPEUTICS INC 38,691 0.0171
ARKG 13 Apr 2022 Buy BEAM BEAM THERAPEUTICS INC 2,574 0.0038
ARKK 13 Apr 2022 Buy BEAM BEAM THERAPEUTICS INC 7,426 0.0035
ARKG 11 Apr 2022 Buy BEAM BEAM THERAPEUTICS INC 4,416 0.0061
ARKK 11 Apr 2022 Buy BEAM BEAM THERAPEUTICS INC 12,538 0.0055
ARKG 20 Jan 2022 Buy BEAM BEAM THERAPEUTICS INC 22,800 0.0375
ARKG 18 Jan 2022 Buy BEAM BEAM THERAPEUTICS INC 75,791 0.1117
ARKK 6 Jan 2022 Buy BEAM BEAM THERAPEUTICS INC 42,300 0.0207
ARKG 5 Jan 2022 Buy BEAM BEAM THERAPEUTICS INC 18,600 0.0263
ARKK 5 Jan 2022 Buy BEAM BEAM THERAPEUTICS INC 14,100 0.0064
ARKG 3 Jan 2022 Buy BEAM BEAM THERAPEUTICS INC 14,400 0.0229
ARKK 3 Jan 2022 Buy BEAM BEAM THERAPEUTICS INC 81,106 0.0395
ARKG 30 Dec 2021 Buy BEAM BEAM THERAPEUTICS INC 5,200 0.0084
ARKG 29 Dec 2021 Buy BEAM BEAM THERAPEUTICS INC 5,855 0.0089
ARKK 27 Dec 2021 Sell BEAM BEAM THERAPEUTICS INC 17,040 0.0082
ARKG 15 Dec 2021 Buy BEAM BEAM THERAPEUTICS INC 15,000 0.0214
ARKK 15 Dec 2021 Buy BEAM BEAM THERAPEUTICS INC 11,432 0.0052
ARKG 6 Dec 2021 Buy BEAM BEAM THERAPEUTICS INC 25,920 0.0300
ARKK 6 Dec 2021 Buy BEAM BEAM THERAPEUTICS INC 2,864 0.0000
ARKG 24 Nov 2021 Buy BEAM BEAM THERAPEUTICS INC 45,262 0.0650
ARKK 24 Nov 2021 Buy BEAM BEAM THERAPEUTICS INC 130,600 0.0582
ARKG 22 Nov 2021 Buy BEAM BEAM THERAPEUTICS INC 67,342 0.0979
ARKG 19 Nov 2021 Buy BEAM BEAM THERAPEUTICS INC 23,300 0.0333
ARKK 19 Nov 2021 Buy BEAM BEAM THERAPEUTICS INC 95,739 0.0436
ARKK 18 Nov 2021 Buy BEAM BEAM THERAPEUTICS INC 9,760 0.0043
ARKK 17 Nov 2021 Buy BEAM BEAM THERAPEUTICS INC 157,464 0.0679
ARKK 16 Nov 2021 Buy BEAM BEAM THERAPEUTICS INC 3,600 0.0016
ARKK 15 Nov 2021 Buy BEAM BEAM THERAPEUTICS INC 32,531 0.0137
ARKK 3 Nov 2021 Buy BEAM BEAM THERAPEUTICS INC 24,803 0.0108
ARKK 2 Nov 2021 Buy BEAM BEAM THERAPEUTICS INC 1,442 0.0006
ARKK 1 Nov 2021 Buy BEAM BEAM THERAPEUTICS INC 10,000 0.0042
ARKG 29 Oct 2021 Buy BEAM BEAM THERAPEUTICS INC 10,117 0.0127
ARKK 28 Oct 2021 Buy BEAM BEAM THERAPEUTICS INC 5,205 0.0022
ARKK 27 Oct 2021 Buy BEAM BEAM THERAPEUTICS INC 47,400 0.0206
ARKK 26 Oct 2021 Buy BEAM BEAM THERAPEUTICS INC 52,895 0.0231
ARKK 25 Oct 2021 Buy BEAM BEAM THERAPEUTICS INC 7,638 0.0034
ARKK 22 Oct 2021 Buy BEAM BEAM THERAPEUTICS INC 45,600 0.0198
ARKK 21 Oct 2021 Buy BEAM BEAM THERAPEUTICS INC 14,943 0.0066
ARKK 20 Oct 2021 Buy BEAM BEAM THERAPEUTICS INC 958 0.0004
ARKK 13 Oct 2021 Buy BEAM BEAM THERAPEUTICS INC 18,429 0.0081
ARKG 12 Oct 2021 Buy BEAM BEAM THERAPEUTICS INC 15,167 0.0198
ARKG 11 Oct 2021 Buy BEAM BEAM THERAPEUTICS INC 23,872 0.0298
ARKG 8 Oct 2021 Buy BEAM BEAM THERAPEUTICS INC 37,753 0.0455
ARKK 8 Oct 2021 Buy BEAM BEAM THERAPEUTICS INC 129,130 0.0536
ARKK 7 Oct 2021 Buy BEAM BEAM THERAPEUTICS INC 85,469 0.0400
ARKG 6 Oct 2021 Buy BEAM BEAM THERAPEUTICS INC 75,862 0.0900
ARKK 6 Oct 2021 Buy BEAM BEAM THERAPEUTICS INC 17,763 0.0100
ARKG 5 Oct 2021 Buy BEAM BEAM THERAPEUTICS INC 12,094 0.0149
ARKK 5 Oct 2021 Buy BEAM BEAM THERAPEUTICS INC 92,397 0.0414
ARKG 1 Oct 2021 Buy BEAM BEAM THERAPEUTICS INC 38,636 0.0468
ARKK 1 Oct 2021 Buy BEAM BEAM THERAPEUTICS INC 95,629 0.0423
ARKG 29 Sep 2021 Buy BEAM BEAM THERAPEUTICS INC 56,108 0.0697
ARKG 28 Sep 2021 Buy BEAM BEAM THERAPEUTICS INC 27,345 0.0332
ARKG 27 Sep 2021 Buy BEAM BEAM THERAPEUTICS INC 93,398 0.1142
ARKG 22 Sep 2021 Buy BEAM BEAM THERAPEUTICS INC 917 0.0011
ARKG 21 Sep 2021 Buy BEAM BEAM THERAPEUTICS INC 33,600 0.0404
ARKG 20 Sep 2021 Buy BEAM BEAM THERAPEUTICS INC 43,400 0.0499
ARKK 17 Sep 2021 Buy BEAM BEAM THERAPEUTICS INC 8,000 0.0038
ARKK 16 Sep 2021 Buy BEAM BEAM THERAPEUTICS INC 15,372 0.0074
ARKG 15 Sep 2021 Buy BEAM BEAM THERAPEUTICS INC 21,500 0.0275
ARKK 15 Sep 2021 Buy BEAM BEAM THERAPEUTICS INC 8,607 0.0041
ARKG 26 Aug 2021 Buy BEAM BEAM THERAPEUTICS INC 17,033 0.0207
ARKG 20 Aug 2021 Buy BEAM BEAM THERAPEUTICS INC 34,871 0.0448
ARKK 20 Aug 2021 Buy BEAM BEAM THERAPEUTICS INC 5,190 0.0025
ARKK 19 Aug 2021 Buy BEAM BEAM THERAPEUTICS INC 44,996 0.0212
ARKK 18 Aug 2021 Buy BEAM BEAM THERAPEUTICS INC 4,174 0.0020
ARKK 17 Aug 2021 Buy BEAM BEAM THERAPEUTICS INC 97,000 0.0448
ARKK 16 Aug 2021 Buy BEAM BEAM THERAPEUTICS INC 47,547 0.0210
ARKG 13 Aug 2021 Buy BEAM BEAM THERAPEUTICS INC 13,452 0.0159
ARKG 10 Aug 2021 Buy BEAM BEAM THERAPEUTICS INC 48,616 0.0551
ARKG 4 Aug 2021 Buy BEAM BEAM THERAPEUTICS INC 17,964 0.0196
ARKG 3 Aug 2021 Buy BEAM BEAM THERAPEUTICS INC 3,074 0.0032
ARKK 3 Aug 2021 Buy BEAM BEAM THERAPEUTICS INC 37,694 0.0148
ARKK 2 Aug 2021 Buy BEAM BEAM THERAPEUTICS INC 81,497 0.0331
ARKK 30 Jul 2021 Buy BEAM BEAM THERAPEUTICS INC 80,161 0.0324
ARKK 29 Jul 2021 Buy BEAM BEAM THERAPEUTICS INC 44,675 0.0177
ARKK 19 Jul 2021 Buy BEAM BEAM THERAPEUTICS INC 1,335 0.0005
ARKK 16 Jul 2021 Buy BEAM BEAM THERAPEUTICS INC 5,151 0.0021
ARKG 7 Jun 2021 Buy BEAM BEAM THERAPEUTICS INC 3,311 0.0033
ARKG 4 Jun 2021 Buy BEAM BEAM THERAPEUTICS INC 5,000 0.0051
ARKK 20 May 2021 Buy BEAM BEAM THERAPEUTICS INC 30,000 0.0108
ARKK 18 May 2021 Buy BEAM BEAM THERAPEUTICS INC 200 0.0001
ARKK 13 May 2021 Buy BEAM BEAM THERAPEUTICS INC 62,169 0.0221
ARKK 11 May 2021 Buy BEAM BEAM THERAPEUTICS INC 84,000 0.0261
ARKK 10 May 2021 Buy BEAM BEAM THERAPEUTICS INC 455,388 0.1484
ARKK 4 May 2021 Buy BEAM BEAM THERAPEUTICS INC 103,836 0.0350
ARKK 3 May 2021 Buy BEAM BEAM THERAPEUTICS INC 16,849 0.0056
ARKK 23 Apr 2021 Buy BEAM BEAM THERAPEUTICS INC 8,386 0.0026
ARKK 22 Apr 2021 Buy BEAM BEAM THERAPEUTICS INC 88,700 0.0277
ARKK 21 Apr 2021 Buy BEAM BEAM THERAPEUTICS INC 37,406 0.0109
ARKK 20 Apr 2021 Buy BEAM BEAM THERAPEUTICS INC 30,087 0.0089
ARKK 19 Apr 2021 Buy BEAM BEAM THERAPEUTICS INC 73,985 0.0219
ARKK 16 Apr 2021 Buy BEAM BEAM THERAPEUTICS INC 52,791 0.0153
Latest Blogs
ARK by Cathie Wood is still suffering a year after its apex.

Cathie Wood's flagship exchange-traded fund hit an all-time high in February of this year. Her preferred disruptive-tech chasing strategy may still be in for a lot of suffering after a year and a 53 percent fall.

After a dramatic decline last month, the ARK Innovation ETF (ticker: ARKK) has steadied off - it's practically flat in February – but the headwinds surrounding its speculative growth picks are just becoming more vital. Many businesses that thrived during the pandemic are being hammered by the economic reopening, not only because yields are rising as investors prepare for the US Federal Reserve to raise interest rates, which is terrible news for unprofitable businesses, but also because the economic reopening is hammering many of the businesses that thrived during the pandemic.

Roku, Teladoc, and Zoom, all winners in the work-from-home era, have had their stock prices plummet by as much as 74% in the past year.

Short bets against ARK, according to IHS Markit data, hit a fresh high of 11.4 percent of outstanding shares this week. The Tuttle Capital Short Innovation ETF (SARK), which beats the ARK, now has assets worth more than $US300 million ($416 million).

"Those equities are supported by speculation, and speculation pays less well when the Fed raises rates," said Brent Schutte, chief investment strategist at Northwestern Mutual Wealth Management Co. "Much of what's happening in the market reminds me of what happened in the late 1990s when market segments were bid up to levels based on future assumptions."

Because its price chart resembles that of the Nasdaq index of technology businesses from more than two decades ago, analogies to that period and the dot-com implosion that followed are becoming more common in discussions of ARK.

"Today marks the 253rd trading day from ARK's all-time high," Jessica Rabe, co-founder of DataTrek Research, wrote in a Tuesday note, "while the Nasdaq was down 60% from its dot-com bubble top on the same day in 2001."

"If 2000/2001 analog holds, we should see ARK continuing to fall over the following three weeks. The Nasdaq dropped 18.7% in the next 16 trading days "recent."

Net flows are positive.

The better news for investors and Ms. Wood is that there may be some immediate respite. The Nasdaq rose 41% in six weeks in 2001 before falling.

The ARK Investment Management did not respond to a request for comment.

Most of ARK's $US15 billion asset loss has been attributed to bad performance, a plus for the company. Since the fund achieved an intraday high of $US159.70 a year ago this week, investors have withdrawn only around $US465 million, and ARK's net flows this year are positive despite a more than 20% drop.

This exceptional loyalty prevents a worsening situation and allows Wood's approach to recovering. The star fund manager has consistently emphasized that her funds have a five-year investment horizon and that she believes in many good options.

Mr. Schutte, on the other hand, says the drop is understandable because several of the company's biggest bets, such as Teladoc and Zoom, are becoming less significant as COVID-19 approaches.

"During the pandemic, there were a lot of questions about what would happen to society and how we'd go about our lives," he added.

"You drew in new investors who wanted to know "what are the upcoming themes I should invest in?" I believe you got a washout of it as well."

On Friday, Cathie Wood sold $148.9 million worth of Palantir stock, halving her exposure.

Ark Investment Management, run by Cathie Wood, sold more Palantir Technologies Inc PLTR -6.39 percent shares on Friday, cutting its stake in the Peter Thiel-backed company.

According to Friday's closing price, the famous investment management firm sold 13.5 million shares of the big data company, valued at $148.9 million.

Palantir's stock fell 6.4 percent to $11.02 per share on Friday. The stock has lost 16% of its value in the last week.

Before Friday's trade, Ark Invest held 25.53 million shares in Palantir, suggesting that the famous stock picker had trimmed over 52 percent of its total keeping a day later.

After the business disclosed lower-than-expected fourth-quarter earnings before the market opened on Thursday, Ark Invest, located in St. Petersburg, California, dumped shares in Palantir for the second time.

The software firm, well-known for its work with government organizations, posted earnings of 2 cents per share, falling short of the analyst consensus of 4 cents. The company recorded quarterly revenues of $432.87 million, higher than the $417.69 million predicted by analysts.

Palantir's stock had been sold for 4.77 million shares by the investment firm the day before.

All six of Ark Invest's active exchange-traded funds own Palantir stock, including the flagship Ark Innovation ETF ARKK -4.88 percent.

Before the recent sell-off, Ark Invest had been stockpiling Palantir shares for months.

Cathie Wood appeared on television to defend her ARK funds' dismal performance. It didn't go quite as planned.

The Ark Innovation ETF (ARKK), Cathie Wood's flagship fund, is down 30% year to date and more volatile than almost any other fund on the market. On CNBC's Halftime Report, Wood jumped at the chance to defend the fund and its deflated price, which is currently $68.80, down from $155 a year ago.

"We've seen a significant decline," Wood said, adding, "We feel innovation is at bargain basement zone." Even though her ETF was underperforming, she emphasized that her companies were still "very inexpensive" and that the current fund loss was temporary. When the call's 40 free minutes were finished, Zoom gave her an extra 10 minutes to complete the interview.

Having Zoom check to see whether she was "running out of time?" Wood, who has been aggressively buying up shares in Zoom and other IT firms that have fallen from their pandemic highs, was unhappy. Zoom, like Wood's other significant tech holdings, Teladoc Health, Roku, and Roblox, is down 20% to 40% year to date as investors worry about rising interest and inflation rates.

However, a significant chunk of the interview was devoted to a personal assault on Cathie Wood, who was named the most excellent stock picker in 2020 by Bloomberg's then-Editor-in-Chief Matthew Winkler after correctly forecasting that Tesla will one day be valued at more than $1 trillion.

Wood bluntly ignored Tuttle Capital Management's Short Innovation ETF (SARK), which tracks the inverse performance of ARKK using swaps contracts for the sole purpose of betting against Cathie Wood's selections. "They're not conducting any research." She explained, "All they're doing is shorting innovation."

Of course, SARK is betting against Cathie Woods, not on innovation. "Well, we stand for invention," Wood responded. The SARK ETF has gained 55 percent since its debut, whereas the ARKK ETF has declined by 42 percent.

Tuttle Capital Management CEO Matthew Tuttle chimed in on the SARK ETF, calling it a "tool" for investors. According to SARK, "to convey a negative view of the market, innovative enterprises, the current rising rate environment, or a [specific] portfolio manager if they wish." "It's un-American not to have options in the marketplace," Tuttle told Insider on Thursday.

In any event, Wood is making progress. Her main concern currently is bearish calls on her ETF. "Our major concern is that our investors convert temporary losses into long-term losses," Wood continued.